CA3175964A1 - Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof - Google Patents

Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof

Info

Publication number
CA3175964A1
CA3175964A1 CA3175964A CA3175964A CA3175964A1 CA 3175964 A1 CA3175964 A1 CA 3175964A1 CA 3175964 A CA3175964 A CA 3175964A CA 3175964 A CA3175964 A CA 3175964A CA 3175964 A1 CA3175964 A1 CA 3175964A1
Authority
CA
Canada
Prior art keywords
brequinar
hours
sodium salt
cancer
brequinar sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3175964A
Other languages
English (en)
French (fr)
Inventor
Abdolsamad Tadayon
Ping Huang
Chaoyi DENG
Jinsuo YANG
Siyi Jiang
Qingqing LU
Lin Cui
Mo JIA
Xianjun You
David P. Hesson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clear Creek Bio Inc
Original Assignee
Clear Creek Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clear Creek Bio Inc filed Critical Clear Creek Bio Inc
Publication of CA3175964A1 publication Critical patent/CA3175964A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3175964A 2020-03-20 2021-03-19 Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof Pending CA3175964A1 (en)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US202062992720P 2020-03-20 2020-03-20
US62/992,720 2020-03-20
US202063020460P 2020-05-05 2020-05-05
US63/020,460 2020-05-05
US202063030677P 2020-05-27 2020-05-27
US63/030,677 2020-05-27
US202063043382P 2020-06-24 2020-06-24
US202063043386P 2020-06-24 2020-06-24
US202063043388P 2020-06-24 2020-06-24
US202063043384P 2020-06-24 2020-06-24
US63/043,384 2020-06-24
US63/043,388 2020-06-24
US63/043,386 2020-06-24
US63/043,382 2020-06-24
PCT/US2021/023350 WO2021189017A1 (en) 2020-03-20 2021-03-19 Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof

Publications (1)

Publication Number Publication Date
CA3175964A1 true CA3175964A1 (en) 2021-09-23

Family

ID=77771654

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3175964A Pending CA3175964A1 (en) 2020-03-20 2021-03-19 Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof

Country Status (5)

Country Link
EP (1) EP4121050A4 (enExample)
JP (1) JP2023518419A (enExample)
AU (1) AU2021236757A1 (enExample)
CA (1) CA3175964A1 (enExample)
WO (1) WO2021189017A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022159763A1 (en) * 2021-01-22 2022-07-28 Model Medicines, Inc. Sars-cov-2 therapeutics
WO2023043830A1 (en) * 2021-09-15 2023-03-23 Clear Creek Bio, Inc. Combination therapies to treat viral infections
CN120131690A (zh) * 2025-03-24 2025-06-13 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 一种布喹那在制备抑制流感病毒的制剂中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05011525A (es) * 2003-04-30 2005-12-12 Nippon Shinyaku Co Ltd Cristales de solvato de derivado de acido quinolincarboxilico.
CA2910112C (en) * 2013-04-25 2021-02-16 Kyorin Pharmaceutical Co., Ltd. Solid pharmaceutical composition
US11096934B2 (en) * 2015-09-01 2021-08-24 The Broad Institute, Inc. Compounds and methods useful for treating or preventing hematological cancers
EP3773579A4 (en) * 2018-03-26 2022-03-09 Clear Creek Bio, Inc. COMPOSITIONS AND METHODS FOR INHIBITING DIHYDROOROTATE DEHYDROGENASE
US20190290634A1 (en) * 2018-03-26 2019-09-26 Clear Creek Bio, Inc. Compositions and methods for inhibiting dihydroorotate dehydrogenase
WO2019246603A1 (en) * 2018-06-22 2019-12-26 Ohio State Innovation Foundation Methods and compositions for inhibition of dihydroorotate dehydrogenase

Also Published As

Publication number Publication date
JP2023518419A (ja) 2023-05-01
EP4121050A1 (en) 2023-01-25
WO2021189017A1 (en) 2021-09-23
EP4121050A4 (en) 2024-04-17
AU2021236757A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
US20250248989A1 (en) Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof
TWI786110B (zh) (s)-2-乙基丁基2-(((s)-(((2r,3s,4r,5r) -5-(4-胺基吡咯并[2,1-f][1,2,4]三嗪-7-基)-5-氰基-3,4-二羥基四氫呋喃-2-基)甲氧基)(苯氧基)磷醯基)胺基)丙酸酯之結晶形式
CN100506790C (zh) 莫达非尼多晶型
CA3175964A1 (en) Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof
CA3069226A1 (en) Methods of treatment for cystic fibrosis
WO2019018353A1 (en) METHODS OF TREATING CYSTIC FIBROSIS
EP3502103B1 (en) Crystal form, salt type of substituted 2-hydro-pyrazole derivative and preparation method therefor
CN110092745B (zh) 一种含芳环的化合物及其应用
CN102190616A (zh) 一种氘代的ω-二苯基脲的合成及生产的方法和工艺
CN111875550B (zh) 法匹拉韦二甲基亚砜溶剂化物的晶型及制备方法
CN102164914A (zh) 用作多巴胺D3受体调节剂的苯并[d]异*唑-3-基-哌嗪衍生物
CN105732615A (zh) Cdk激酶抑制剂
CN101597271A (zh) 艾拉莫德的衍生物,其制备方法和药物应用
CN107540710A (zh) 肝递送抗病毒前体药物核苷环磷酸酯化合物及应用
CN109651377A (zh) 一种治疗癌症的化合物及其用途
CN105566332B (zh) 巴瑞克替尼三氟乙酸盐a晶型和b晶型及其制备方法
CN105820130B (zh) 三氮唑正丙酸类urat1抑制剂、制备方法及其在高尿酸血症和痛风治疗上的用途
JP2010516668A (ja) 抗ウイルス剤のマレイン酸モノ塩及びそれを含有する医薬組成物
CN108285431B (zh) 一种吡非尼酮有关物质及其制备方法和用途
SA06270462B1 (ar) مركبات وطرق لتثبيط التفاعل بين بروتين bcl وشركاء الارتباط
CN116284179B (zh) 淫羊藿次苷ii衍生物的制备及应用
CN116239570B (zh) 一种半琥珀酸拉司米地坦新晶型
CN113825758B (zh) 抗HBV的四氢异噁唑并[4,3-c]吡啶类化合物的晶型
CN102414216A (zh) 1-(2’-氰基-2’-脱氧-β-D-阿拉伯呋喃糖基)胞嘧啶一盐酸盐的新型稳定型结晶
CN121159545A (zh) 一种巴瑞克替尼与间苯二甲酸共晶二氯甲烷溶剂合物及其制备方法

Legal Events

Date Code Title Description
D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250307

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250307

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250307

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250321

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250321

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250321

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250324

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250331

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250331

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250331

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250430

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250514

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251127

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20260224